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Thank you, Dr. Cole. It is indeed an honor to be invited to attend this important
event.
What are the perspectives of the American Cancer Society in relation to the
National Cancer Program-in particular, the comprehensive cancer centers?
Our purpose as a voluntary health agency is to fight cancer in all ways, to mobilize,
to serve as a catalytic agent for individuals, institutions and government.
In 1937, intense lobbying by the society for a greater federal emphasis on cancer
encouraged the Congress to select cancer as the first categorical disease institute of
NIH. Over the years, the society became the ombudsman for the NCI before
Congress, the White House and the public. We continued to serve as representatives
of the private sector by encouraging the Senate panel ofconsultants on the conquest
of cancer, by speaking up for the principles set forth in the panel's report, and by
becoming the advocate during the National Cancer Act legislative process.
We fought particularly for identification in the law of comprehensive cancer
centers and cancer control, as separate considerations, and won. The society initiated
and co-sponsored with NCI a national conference on cancer centers to explore their
potential and update the developmental process.
The concept of a comprehensive center serving as experts in research, treatment,
education and rehabilitation in cancer isn't new. The late Dr. Sidney Farber-longa
leader in the society- in 1964 stressed the idea ofcenters ofspecial capabilities when
he was a member of President Johnson's Commission on Heart Disease, Cancerand
Stroke. Today, of the 18 comprehensive cancer centers strategically located around
the country, some are moving ahead rapidly, some more slowly, a few are too new to
evaluate.
The most successful centers share a close, cooperative, mutually respectful rela-
tionship with all parts ofthe community including the local divisions and units ofthe
American Cancer Society in the community based cancer control programs and
cancer information services, and other programs.
Here at Yale there has been an excellent relationship between the comprehensive
cancer center and the Connecticut division ofthe society. Yale is certainly one ofthe
foremost medical institutions in the world while the Connecticut division of the
American Cancer Society is one of the best we have in the United States. The two
working together provide the needed synergism.
Physicians and scientists ofthe Yale Comprehensive Cancer Center have served as
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All rights of reproduction in any form reserved.volunteers of the American Cancer Society in many different capacities at the
national and local levels. They understand intimately the programs and resources of
the society and know how to blend these with the mission of the center..
Yale will undoubtedly become the exemplar of comprehensive cancer centers. Its
leadership guarantees success because it has a special sensitivity and commitment.
There has been a fine relationship between Yale and the American Cancer Society
since 1946. In the past 30 years, the American Cancer Society awarded 285 research
grants to Yale totaling more than $11 million.
Dr. Robert Handschumacher served as an American Cancer Society research
professor from 1964 to 1974 and currently Dr. Joseph Bertino is an American Cancer
Society research professor. He will shortly become the chairman ofthe most senior of
all the research advisory committees of the society.
In the past 10 years, Yale was awarded 22 American Cancer Society clinical
fellowships in cancer. Many of these physicians have since become distinguished
oncologists.
On behalf of the American Cancer Society, may I wish you godspeed and assure
you of our continuing support in the years to come.
Arthur I. Holleb, M.D.
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